Reply to the letter to the editor 'management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al.
Department of Oncology/Hematology, Kantonsspital St Gallen, St Gallen, Switzerland silke.gillessen@kssg.ch.
S
S
Gillessen
Department of Nuclear Medicine, Policlinico S. Orsola-University of Bologna, Bologna, Italy.
S
S
Fanti
Department of Oncology/Hematology, Kantonsspital St Gallen, St Gallen, Switzerland.
A
A
Omlin
D000230:Adenocarcinoma / Q000628:therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use*
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D043823:Taxoids